Based on the immunohistochemistry (IHC) expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), BC is classified into hormone receptor-positive BC (luminal), constituting approximately 70% of BC instances; HER2-enriched BC (HER2-E), accounting for 15% to 20% of BC cases; and triple-negative BC (TNBC), which makes up 15% of BC cases [9,10,11,12]. This evidence concerns the gene NR4A1 and breast cancer.